Duloxetine Delayed-Release Capsules, 60mg recall — Breckenridge Pharmaceutical, Inc. (Class II)

Breckenridge Pharmaceutical, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Duloxetine Delayed-Release Capsules, 60mg — a Class II recall, initiated 2026-06-04 and posted to the FDA enforcement report on 2026-06-17, under recall number D-0583-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit”. From the product description, the form is delayed-release capsules, the strength given is 60mg, the package is described as 90 Capsules (NDC 51991-748-90) and 1000 Capsules (51991-748-10) and it is marked Rx only. 1 National Drug Code number is printed in the record: 51991-748-90. Distribution is recorded as “Nationwide within the United States” — Nationwide (US), with the recalling firm on record in NJ, United States. The FDA files it under event ID 99108 together with 1 other recall number, all listed and linked below. Within that event this is the strength 60mg, package 90 Capsules (NDC 51991-748-90) · 1000 Capsules (51991-748-10) and ndc 51991-748-90 configuration; the sibling records differ on strength, package and ndc and match on everything else the source states. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0583-2026
FDA event ID 99108 (2 recall numbers)
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Breckenridge Pharmaceutical, Inc.
Recall initiated 2026-06-04
Reported by FDA 2026-06-17
Report lag 13 days from initiation to report
Distribution Nationwide within the United States — Nationwide (US)
Firm location on record NJ, United States
Product description (source) Duloxetine Delayed-Release Capsules, USP, 60mg, packaged in a) 90 Capsules (NDC 51991-748-90); b) 1000 Capsules (51991-748-10), Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.

Reason reported by FDA

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

11 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

6 identifying values matched by exact pattern in the 36-word product description above; each is a literal substring of it.

Product named Duloxetine Delayed-Release Capsules
Form Delayed-Release Capsules
Strength 60mg
Package 90 Capsules (NDC 51991-748-90) · 1000 Capsules (51991-748-10)
NDC 51991-748-90
Marketing category Rx only

Which configuration this record is

2 recall numbers share event 99108. They differ on strength, package and ndc and agree on everything else the source states, so those are the values to check a package against.

Attribute This record (D-0583-2026) D-0582-2026
Strength 60mg 30mg
Package 90 Capsules (NDC 51991-748-90) · 1000 Capsules (51991-748-10) 1000 Capsule
NDC 51991-748-90 51991-747-10

Shared across all 2 records under this event: form Delayed-Release Capsules; product named Duloxetine Delayed-Release Capsules; fda tier Class II; recalling firm Breckenridge Pharmaceutical, Inc.; the same reason text; initiated 2026-06-04; reported 2026-06-17.

Event context: 2 recall numbers under event 99108

One enforcement action, 2 recall numbers: the FDA filed 1 further configuration of this action under event 99108. Each keeps its own recall number and dates.

Recall recordRecall numberFDA tierStrength / formNDCReported
Duloxetine Delayed-Release Capsules, 30mgD-0582-2026Class II30mg · Delayed-Release Capsules51991-747-102026-06-17

Other indexed recalls from Breckenridge Pharmaceutical, Inc.

3 indexed records name Breckenridge Pharmaceutical, Inc. as the recalling firm, across 2 FDA events, reported 2026-05-13 to 2026-06-17. A coverage-limited activity count over the ingested window, not a quality rating.

Recall recordRecall numberFDA tierStrength / formReported
Duloxetine Delayed-Release Capsules USP, 60mgD-0522-2026Class II60mg · Delayed-Release Capsules2026-05-13

Other indexed recalls of duloxetine

6 indexed records name duloxetine as the recalled substance. Matching is on the product-name prefix of the FDA's own text, so other strengths and packages are included.

Recall recordRecall numberRecalling firmStrength / formReported
Duloxetine Delayed-Release Capsules, 30 mgD-0514-2026Ajanta Pharma Ltd.30 mg · Delayed-Release Capsules2026-05-13
Duloxetine Delayed-Release Capsules, 60 mgD-0515-2026Ajanta Pharma Ltd.60 mg · Delayed-Release Capsules2026-05-13
Duloxetine Delayed-Release Capsules, 20 mgD-0516-2026Ajanta Pharma Ltd.20 mg · Delayed-Release Capsules2026-05-13

Reported in the same month (2026-06)

74 enforcement reports carry a report date in 2026-06; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Zep, 70%D-0586-2026Zep IncClass II2026-06-17
GSMS Incorporated, 1,000 MGD-0587-2026Golden State Medical Supply Inc.Class II2026-06-17
Minocycline Hydrochloride Extended-Release Tablets, 115 mgD-0597-2026Ascend Laboratories, LLCClass II2026-06-17
Budesonide Inhalation Suspension, 1mg/2mLD-0607-2026Sun Pharmaceutical Industries IncClass II2026-06-17
Lidocaine HCl Injection USPD-0554-2026Spectra Medical Devices, LLCClass II2026-06-10
Duloxetine DR Capsules, 30 mgD-0555-2026Asclemed Usa Inc.Class II2026-06-10
Amlodipine and Olmesartan Medoxomil Tablets, 5mg/40mgD-0556-2026Ascend Laboratories, LLCClass II2026-06-10
KIRKLAND Signature, 1000 mgD-0557-2026Guardian Drug Co. Inc.Class II2026-06-10

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 3 nearest to 2026-06-17 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
HALEON CALCIUM CARBONATE TUMS ANTACID, 1000 mgD-0558-2026Guardian Drug Co. Inc.1000 mg · Tablets2026-06-10
HALEON CALCIUM CARBONATE TUMS ANTACID, 750 mgD-0559-2026Guardian Drug Co. Inc.750 mg · Tablets2026-06-10
Good Neighbor Pharmacy, 750 mgD-0560-2026Guardian Drug Co. Inc.750 mg2026-06-10

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. A search on event 99108 returns all 2 of these recall numbers; a search on D-0583-2026 returns only this configuration. Match a package against 51991-748-90 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Breckenridge Pharmaceutical, Inc. (3 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0583-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0583-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-06-17
Ingested
2026-08-22
Record hash
9ea1c50f4d3b2e2a

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.